ProQR Therapeutics (PRQR)
Develops Axiomer RNA-editing medicines, led by AX-0810 for cholestatic diseases.
$1.70
After hours+0.01 (+0.59%)
At close$1.69(−11.05%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 57.65% | 60.74M ADS | |
|---|---|---|---|
| 71 holders · as of Jun 30, 2026 | |||
| Insiders | 2.33% | 2.46M ADS | |
| 6 holders · as of Aug 3, 2026 | |||
| Other | 40.02% | 42.17M ADS | |
| remainder | |||
105.36M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
71 holders · 60.74M shares · 14 new positions · 38 increased · 11 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 9.02M | 8.56% | +2.76M | Aug 14, 2026 |
| Abrdn PLC | 8.93M | 8.48% | +5.62M | Jul 31, 2026 |
| Affinity Asset Advisors, LLC | 5.54M | 5.26% | +3.09M | Aug 13, 2026 |
| Privium Fund Management B.V. | 5.52M | 5.24% | +52.9K | Aug 7, 2026 |
| Ikarian Capital, LLC | 3.43M | 3.25% | +1.93M | Aug 14, 2026 |
| Woodline Partners LP | 3.28M | 3.11% | +3.28Mnew | Aug 14, 2026 |
| Heights Capital Management, Inc | 2.76M | 2.62% | +2.76Mnew | Aug 14, 2026 |
| Morgan Stanley | 1.77M | 1.68% | +467.4K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Stichting Administratiekantoor Abchrysincl. A. van Herk Holding B.V., Adrianus van Herk +6 more | 10.90% | 15.38M | 13D | Jul 29, 2026 |
| Aberdeen Group plc | 6.33% | 8.93M | 13G | Jul 29, 2026 |
| Adage Capital Management, L.P. | 6.27% | 6.60M | 13G | Aug 12, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 31, 2026 | Daniel Anton de Boerdirector, officer: Chief Executive Officer | Purchase | 200,000 | $1.77 | 500,000 |
| Jul 17, 2026 | Bart Filiusdirector | Purchase | 150,000 | $1.72 | 300,000 |
| Jul 9, 2026 | Daniel Anton de Boerdirector, officer: Chief Executive Officer | Purchase | 150,000 | $1.74 | 300,000 |
| Jul 7, 2026 | Daniel Anton de Boerdirector, officer: Chief Executive Officer | Purchase | 150,000 | $1.59 | 150,000 |
| Jun 26, 2026 | Bart Filiusdirector | Purchase | 150,000 | $1.54 | 150,000 |
House and Senate disclosures
Not reported.